LA JOLLA, Calif., April 22, 2020 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient?s innate immune system to fight disease, announced today that the United States Patent and Trademark Office (USPTO) has given formal notice of allowance in patent application serial no. 15/268,399, titled ?IN VIVO PRIMING OF NATURAL KILLER CELLS,? which covers a method of treating cancer by administering a proprietary inactivated cellular material preparation and contacting a patient?s own natural killer cells within the body to induce an in vivo response, namely, the priming of NK cells for enhancing innate immunity and the NK cell ability to recognize and kill cancer cells within the patient.
News
INmune Bio Inc. Announces USPTO Allowance of Key Patent Covering Its DN-TNFa Platform Technology for Treating Cancer
LA JOLLA, Calif., Sept. 12, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that reprogram the patient?s innate immune system to fight disease, announced today that the Un… […]
News
Correction: INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Over-Allotment Option
LA JOLLA, Calif., July 20, 2020 (GLOBE NEWSWIRE) — In a release issued under the same headline on Monday, July 20th by INmune Bio, Inc. (NASDAQ: INMB) was incorrectly reported with below sentence: […]
News
INmune Bio, Inc. Reports Third Quarter 2019 Financial Results and Provides Shareholder Update
LA JOLLA, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc.?(NASDAQ:?INMB) (the ?Company?),?an immunology company developing treatments that harness the patient?s innate immune system to fight disease, today reported its financial results fo… […]
